{'fraction_non_alphanumeric': 0.020054694621695533, 'fraction_numerical': 0.0027347310847766638, 'mean_word_length': 5.168539325842697, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Genetic polymorphisms and their influence on pancreatic adenocarcinoma progression

Pancreatic adenocarcinoma (PA) is one of the most fatal cancers since it shows little to no symptoms until it has metastasized. As is true with most malignancies, an early detection and diagnosis is imperative in order to help increase survival rate. Although there are several extant treatments available, their success depends on an early diagnosis. In order to identify genetic loci that may assist in early diagnosis, we analyzed 134 DNA sequences of patients with various stages of PA. NCBI’s Gene Expression Omnibus was used to obtain PA microarray data to identify overexpressed genes. The Sequence Read Archive (SRA) database was then used to provide sequenced data of a PA cohort which was then mapped, indexed and called. With these analyses, we were able to identify single nucleotide polymorphisms (SNPs) that were specific to PA primary, secondary, or metastatic tumors. These results advance our understanding of the development of PA and highlight target sites that could influence PA tumor stages.